Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C

Journal of Hepatology

Volumn 66, Issue 4, 2017, Pages 718-723

  Fernández, Inmaculada ^a   Muñoz Gómez, Raquel ^a   Pascasio, Juan M ^b   Baliellas, Carme ^c   Polanco, Natalia ^a   Esforzado, Nuria ^d   Arias, Ana ^e   Prieto, Martín ^f   Castells, Lluis ^g   Cuervas Mons, Valentín ^e   Hernández, Olga ^a   Crespo, Javier ^h   Calleja, José L ^e   Forns, Xavier ⁱ   Londoño, María Carlota ⁱ  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

ⁱ INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Direct acting antivirals; Hepatitis C; Immunosuppressive therapy; Liver transplant; Renal transplantation

Indexed keywords

ANTIVIRUS AGENT; CREATININE; DACLATASVIR; DASABUVIR; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; INTERFERON;

ACUTE GRAFT REJECTION; ADULT; ADVERSE DRUG REACTION; AGED; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; REGISTER; RETROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; GLOMERULUS FILTRATION RATE; KIDNEY TRANSPLANTATION; MIDDLE AGED; PATHOPHYSIOLOGY; SPAIN; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSION; INTERFERONS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SPAIN; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 85010976125     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.12.020     Document Type: Article

References (19)

1. [1] Morales, J.M., Fabrizi, F., Hepatitis C and its impact on renal transplantation. Nat Rev Nephrol 11 (2015), 172–182.
2. [2] Fabrizi, F., Verdesca, S., Messa, P., Martin, P., Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. Dig Dis Sci 60 (2015), 3801–3813.
3. [3] Ladino, M., Pedraza, F., Roth, D., Hepatitis C virus infection in chronic kidney disease. J Am Soc Nephrol 27 (2016), 2238–2246.
4. [4] Fabrizi, F., Penatti, A., Messa, P., Martín, P., Treatment of hepatitis C after kidney transplant: a pooled analysis of observational studies. J Med Virol 86 (2014), 933–940.
5. [5] Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Guideline 4: Management of HCV-infected patients before and after kidney transplantation. Kidney Int 73 (2008), S53–S68.
6. [6] Younossi, Z.M., Stepanova, M., Marcellin, P., Afdhal, N., Kowdley, K.V., Zeuzem, S., et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. Hepatology 61 (2015), 1798–1808.
7. [7] Feld, J.J., Kowdley, K.V., Coakley, E., Sigal, S., Nelson, D.R., Crawford, D., et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370 (2014), 1594–1603.
8. [8] Forns, X., Charlton, M., Denning, J., McHutchison, J.G., Symonds, W.T., Brainard, D., et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 61 (2015), 1485–1494.
9. [9] Charlton, M., Everson, G.T., Flamm, S.L., Kumar, P., Landis, C., Brown, R.S. Jr, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
10. [10] Kamar, N., Marion, O., Rostaing, L., Cointault, O., Ribes, D., Lavayssiere, L., et al. Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant 16 (2016), 1474–1479.
11. [11] Sawinski, D., Kaur, N., Ajeti, A., Trofe-Clark, J., Lim, M., Bleicher, M., et al. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant 16 (2016), 1588–1595.
12. [12] Bedosa, P., Poynard, T., An algorithm for the grading of activity in cronic hepatitis C. The Metavir Cooperative Study Group. Hepatology 24 (1996), 289–293.
13. [13] Levey, A.S., Stevens, L.A., Schmid, C.H., Zhang, Y.L., Castro, A.F. 3rd, Feldman, H.I., et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 150 (2009), 604–612.
14. [14] Colombo, M., Aghemo, A., Liu, H., Zhang, J., Dvory-Sobol, H., Hyland, R., et al. Treatment with Ledipasvir-Sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection. A randomized trial. Ann Intern Med, 2016, 10.7326/M16-1205.
15. [15] Saxena, V., Terrault, N.A., Treatment of hepatitis C infection in renal transplant recipients: the long wait is over. Am J Transplant 16 (2016), 1345–1347.
16. [16] Kwo, P.Y., Mantry, P.S., Coakley, E., Te, H.S., Vargas, H.E., Brown, R. Jr, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 371 (2014), 2375–2382.
17. [17] Wolffenbuttel, L., Poli, D.D., Manfro, R.C., Goncalves, L.F., Cyclosporine pharmacokinetics in anti-HCV + patients. Clin Transplant 18 (2004), 654–660.
18. [18] Bhamidimarri, K.R., Martín, P., Levy, C., Roth, D., Renal function decline is frequent in patients undergoing hepatitis C treatment post kidney transplant. EASL 2016. J Hepatol 64 (2016), S784–S785.
19. [19] Saxena, V., Koraishy, F.M., Sise, M.E., Lim, J.K., Schmidt, M., Chung, R.T., et al. HCV-TARGET. Safety and efficacy of sofosbuvir containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 36 (2016), 807–816.